Belite Bio Yönetim

Yönetim kriter kontrolleri 2/4

Belite Bio CEO'su Tom Lin, Nov2021 tarihinde atandı, in görev süresi 4.42 yıldır. şirketin hisselerinin 0.9% doğrudan sahiptir ve bu hisselerin değeri $ 63.11M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.4 yıl ve 4 yıldır.

Anahtar bilgiler

Tom Lin

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	4.4yrs
CEO sahipliği	0.9%
Yönetim ortalama görev süresi	4.4yrs
Yönetim Kurulu ortalama görev süresi	4yrs

Son yönetim güncellemeleri

Recent updates

Oral Retinal Therapy Potential Will Reshape Long Term Outlook For This Pre Revenue Biotech

Mar 05Catalysts About Belite Bio Belite Bio is a clinical stage biopharmaceutical company focused on oral therapies for retinal and liver diseases. What are the underlying business or industry changes driving this perspective?

We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn

Jul 02

Belite Bio down 21% after disappointing mid-stage results of rare eye disease candidate

Oct 03

Belite seeks FDA nod to proceed with phase 3 trial of genetic eye disease treatment

Jul 19

CEO

Tom Lin (47 yo)

4.4yrs

Görev süresi

Dr. Yu-Hsin Lin, also known as Tom, MBA MMed PhD (Med) is the founder and has served as Director of Belite Bio, Inc since March 2018 and its Chairman and served as the Chief Executive Officer since Novembe...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yu-Hsin Lin	Chairman of the Board of Directors & CEO	4.4yrs	Veri yok	0.90% $ 63.1m
Hao-Yuan Chuang	CFO & Director	6yrs	Veri yok	0.75% $ 52.8m
Nathan Mata	Chief Scientific Officer	4.4yrs	Veri yok	0.085% $ 6.0m
Hendrik Scholl	Chief Medical Officer	1.6yrs	Veri yok	Veri yok

4.4yrs

Ortalama Görev Süresi

51.5yo

Ortalama Yaş

Deneyimli Yönetim: BLTE 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yu-Hsin Lin	Chairman of the Board of Directors & CEO	8.1yrs	Veri yok	0.90% $ 63.1m
Hao-Yuan Chuang	CFO & Director	4.4yrs	Veri yok	0.75% $ 52.8m
Frank Holz	Member of Ophthalmology Clinical Advisory Board	no data	Veri yok	Veri yok
Yuan Lu	Independent Director	4yrs	Veri yok	Veri yok
Quan Dong Nguyen	Member of Ophthalmology Clinical Advisory Board	no data	Veri yok	Veri yok
Michel Michaelides	Member of Ophthalmology Clinical Advisory Board	no data	Veri yok	Veri yok
Wan-Shan Chen	Director	4.4yrs	Veri yok	0.086% $ 6.0m
John Longo	Independent Director	4yrs	Veri yok	Veri yok
Gary Biddle	Independent Director	4yrs	Veri yok	Veri yok
Xiao-Hui Chen	Director	1yr	Veri yok	0.0010% $ 71.7k
Robyn Guymer	Member of Ophthalmology Clinical Advisory Board	no data	Veri yok	Veri yok

4.0yrs

Ortalama Görev Süresi

47yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: BLTE 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/04/09 11:40
Gün Sonu Hisse Fiyatı	2026/04/09 00:00
Kazançlar	2025/12/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Belite Bio, Inc 11 Bu analistlerden 7, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Bruce Jackson	Benchmark Company
Tazeen Ahmad	BofA Global Research
Jennifer Kim	Cantor Fitzgerald & Co.

Belite Bio Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Belite Bio, Inc, Annual General Meeting, Apr 15, 2025

Key Executive notifies of intention to sell stock

Director notifies of intention to sell stock

Belite Bio Announces Appointment of Hendrik P. N. Scholl as Chief Medical Officer

Key Executive notifies of intention to sell stock

CFO & Director notifies of intention to sell stock

Recent updates

Forecast breakeven date pushed back to 2028

Oral Retinal Therapy Potential Will Reshape Long Term Outlook For This Pre Revenue Biotech

Price target increased by 10% to US$212

Forecast breakeven date moved forward to 2027

Belite Bio, Inc Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)

Forecast to breakeven in 2028

New minor risk - Shareholder dilution

Belite Bio, Inc. Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease

Forecast to breakeven in 2027

Belite Bio, Inc has completed a Follow-on Equity Offering in the amount of $15.00005 million.

Price target increased by 13% to US$106

Belite Bio Inc. Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for Treatment of Stargardt Disease with Tinlarebant

Belite Bio, Inc. Announces China NMPA Agrees to New Drug Application with Priority Review Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant

Belite Bio Inc. Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease

Belite Bio, Inc announced that it expects to receive $124.999936 million in funding from RA Capital Management, L.P., Eventide Asset Management, LLC, Marshall Wace LLP, RTW Investments, LP, Soleus Capital LLC, Vestal Point Capital, LP

Belite Bio, Inc has filed a Follow-on Equity Offering in the amount of $15.00005 million.

Now 20% overvalued after recent price rise

Price target increased by 10% to US$93.75

We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn

Belite Bio, Inc. Announces Completion of Enrollment in the Pivotal Global Phase 3 Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy

Belite Bio, Inc. Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease

Price target increased by 7.3% to US$85.00

No longer forecast to breakeven

Belite Bio, Inc, Annual General Meeting, Apr 15, 2025

No longer forecast to breakeven

New minor risk - Shareholder dilution

Belite Bio, Inc. Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON Trial of Tinlarebant in Adolescent Stargardt Disease Subjects

New minor risk - Profitability

Belite Bio, Inc has filed a Follow-on Equity Offering.

Forecast to breakeven in 2027

New minor risk - Share price stability

Price target increased by 18% to US$66.75

Key Executive notifies of intention to sell stock

Director notifies of intention to sell stock

Belite Bio Announces Appointment of Hendrik P. N. Scholl as Chief Medical Officer

Key Executive notifies of intention to sell stock

CFO & Director notifies of intention to sell stock

Belite Bio, Inc. Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting

Belite Bio, Inc has filed a Follow-on Equity Offering in the amount of $24.999964 million.

Director notifies of intention to sell stock

Belite Bio, Inc Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan

Chief Scientific Officer notifies of intention to sell stock

CFO & Director notifies of intention to sell stock

Director notifies of intention to sell stock

Key Executive notifies of intention to sell stock

Key Executive notifies of intention to sell stock

New minor risk - Shareholder dilution

New major risk - Share price stability

Price target decreased by 21% to US$45.67

Belite Bio, Inc. Doses First Subject in Pivotal Phase 3 Phoenix Trial Evaluating Oral Tinlarebant for Ga

Belite Bio, Inc. Completes Enrollment in Pivotal Global Phase 3 Dragon Trial Evaluating Oral Tinlarebant for Stargardt Disease

Belite Bio, Inc to Report Q1, 2023 Results on May 10, 2023

Belite Bio, Inc Finalizes Phase 3 Clinical Trial Plans for Advanced Dry AMD Treatment with Tinlarebant (LBS-008)

Less than half of directors are independent

Belite Bio down 21% after disappointing mid-stage results of rare eye disease candidate

Belite Bio, Inc Presents 12-Month Interim Results of LBS-008 Phase 1b/2 Study in Adolescent Stargardt Disease At AAO Annual Meeting 2022

Belite Bio Receives Approval of Lbs-008 Phase 3 Clinical Trial in China

Belite Bio receives approval of begin LBS-008 phase 3 trial in China

Belite Bio Initiates Pivotal Phase 3 Clinical Trial of Lbs-008 in Stargardt Disease in the U.S

Belite Bio adds 15% as pivotal trial for lead asset starts in U.S.

Belite Bio GAAP EPS of -$0.23 beats by $0.05

Belite Bio, Inc to Report Q2, 2022 Results on Aug 10, 2022

Belite Bio, Inc Submits Investigational New Drug Application to FDA for Approval to Proceed with LBS-008 Phase 3 Clinical Trial for the Treatment of Stargardt Disease

Belite seeks FDA nod to proceed with phase 3 trial of genetic eye disease treatment

Belite Bio, Inc Presents Interim Results of LBS-008 Phase 1b/2 Study in Adolescent STGD1 at ARVO Annual Meeting 2022

Belite Bio Receives FDA Fast Track Designation For LBS-008

No independent directors

CEO

Liderlik Ekibi